Does partial normalization of components of metabolic syndrome influence prevalent echocardiographic abnormalities : the HyperGEN study?
There is a little impact of control by treatment of single components of MetS (namely hypertension) on echocardiographic abnormalities. Lower blood pressure in participants with MetS by history was not associated with substantially reduced alterations in cardiac geometry and function.
Glibenclamide and glimepiride are potential ligands of FXR and modulate activation and signaling.